Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cogent Biosciences, Inc.UMRX · Entity 3793 | Chief Scientific Officer | February 11, 2020 | February 13, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cogent Biosciences, Inc.
Report date February 11, 2020 · Filed February 13, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.80 · Expires 2030-02-11 | Direct | 153,600 |
Reported balance
After 2020-02-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-02-11 · Grant · Acquired 153,600 · Balance 153,600 F1: 25% of the shares vests on February 11, 2021, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares vests on February 11, 2021, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 11, 2020 Filed Feb 13, 2020 21:53 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | GrantStock Option · Derivative | 153,600 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001209191-20-009285 · doc4.xml · derivative · entry 1 Ettenberg Seth · CIK 0001734419 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,600 Underlying: Common Stock · 153,600 shares Expires 2030-02-11 F1 · derivative.exercise_date: 25% of the shares vests on February 11, 2021, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer. Read SEC document |
| November 19, 2019 Filed Nov 22, 2019 01:52 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 280,000 | $0.00 Strike: $0.69 | $0.00 |
DisclosureSEC source: 0001209191-19-057694 · doc4.xml · derivative · entry 1 Ettenberg Seth · CIK 0001734419 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,000 Underlying: Common Stock · 280,000 shares Expires 2029-11-19 F1 · derivative.exercise_date: 25% of the shares vests on November 19, 2020, and the remaining shares shall vest in 24 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 20:23 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 11,485 | $0.00 Strike: $0.18 | $0.00 |
DisclosureSEC source: 0001209191-19-021324 · doc4.xml · derivative · entry 3 Ettenberg Seth · CIK 0001734419 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,145 Underlying: Common Stock · 11,485 shares Expires 2025-01-28 F3 · derivative.exercise_date: 25% of the shares vests on September 3, 2015, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 20:23 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | SaleCommon Stock | 11,485 | $4.12 | $47,334.28 |
DisclosureSEC source: 0001209191-19-021324 · doc4.xml · nonDerivative · entry 2 Ettenberg Seth · CIK 0001734419 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.00 to $4.39, inclusive. The reporting person undertakes to provide to Unum Therapeutics Inc., any security holder of Unum Therapeutics Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 20:23 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | Exercise / conversionCommon Stock | 11,485 | $0.18 | $2,067.30 |
DisclosureSEC source: 0001209191-19-021324 · doc4.xml · nonDerivative · entry 1 Ettenberg Seth · CIK 0001734419 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,485 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 25, 2019 Filed Apr 3, 2019 20:13 UTC Amendment | Cogent Biosciences, Inc. UMRX · Entity 3793 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,485 | $0.00 Strike: $0.18 | $0.00 |
DisclosureSEC source: 0001209191-19-023074 · doc4a.xml · derivative · entry 1 Ettenberg Seth · CIK 0001734419 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,145 Underlying: Common Stock · 11,485 shares Expires 2025-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares vests on September 3, 2015, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer. Read SEC document |
| March 01, 2019 Filed Apr 11, 2019 20:30 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 69,700 | $0.00 Strike: $4.36 | $0.00 |
DisclosureSEC source: 0001209191-19-024361 · doc4.xml · derivative · entry 1 Ettenberg Seth · CIK 0001734419 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,700 Underlying: Common Stock · 69,700 shares Expires 2029-03-01 F1 · derivative.exercise_date: 25% of the shares vests on March 1, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 21:36 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,485 | $0.00 Strike: $0.18 | $0.00 |
DisclosureSEC source: 0001209191-19-013558 · doc4.xml · derivative · entry 3 Ettenberg Seth · CIK 0001734419 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,630 Underlying: Common Stock · 11,485 shares Expires 2025-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares vests on September 3, 2015, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 21:36 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | SaleCommon Stock | 11,485 | $4.25 | $48,852.60 |
DisclosureSEC source: 0001209191-19-013558 · doc4.xml · nonDerivative · entry 2 Ettenberg Seth · CIK 0001734419 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.12 to $4.37, inclusive. The reporting person undertakes to provide to Unum Therapeutics Inc., any security holder of Unum Therapeutics Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 21:36 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | Exercise / conversionCommon Stock | 11,485 | $0.18 | $2,067.30 |
DisclosureSEC source: 0001209191-19-013558 · doc4.xml · nonDerivative · entry 1 Ettenberg Seth · CIK 0001734419 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,485 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 26, 2018 Filed Dec 29, 2018 00:09 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,485 | $0.00 Strike: $0.18 | $0.00 |
DisclosureSEC source: 0000899243-18-031952 · doc4.xml · derivative · entry 3 Ettenberg Seth · CIK 0001734419 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,115 Underlying: Common Stock · 11,485 shares Expires 2025-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares vests on September 3, 2015, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer. Read SEC document |
| December 26, 2018 Filed Dec 29, 2018 00:09 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | SaleCommon Stock | 11,485 | $4.05 | $46,486.69 |
DisclosureSEC source: 0000899243-18-031952 · doc4.xml · nonDerivative · entry 2 Ettenberg Seth · CIK 0001734419 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.00 to $4.36, inclusive. The reporting person undertakes to provide to Unum Therapeutics Inc., any security holder of Unum Therapeutics Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 26, 2018 Filed Dec 29, 2018 00:09 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | Exercise / conversionCommon Stock | 11,485 | $0.18 | $2,067.30 |
DisclosureSEC source: 0000899243-18-031952 · doc4.xml · nonDerivative · entry 1 Ettenberg Seth · CIK 0001734419 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,485 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 26, 2018 Filed Nov 27, 2018 00:54 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,485 | $0.00 Strike: $0.18 | $0.00 |
DisclosureSEC source: 0001209191-18-059969 · doc4.xml · derivative · entry 3 Ettenberg Seth · CIK 0001734419 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,600 Underlying: Common Stock · 11,485 shares Expires 2025-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares vests on September 3, 2015, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer. Read SEC document |
| November 26, 2018 Filed Nov 27, 2018 00:54 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | SaleCommon Stock | 11,485 | $7.00 | $80,444.39 |
DisclosureSEC source: 0001209191-18-059969 · doc4.xml · nonDerivative · entry 2 Ettenberg Seth · CIK 0001734419 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.79 to $7.41, inclusive. The reporting person undertakes to provide to Unum Therapeutics Inc., any security holder of Unum Therapeutics Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 26, 2018 Filed Nov 27, 2018 00:54 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | Exercise / conversionCommon Stock | 11,485 | $0.18 | $2,067.30 |
DisclosureSEC source: 0001209191-18-059969 · doc4.xml · nonDerivative · entry 1 Ettenberg Seth · CIK 0001734419 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,485 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 25, 2018 Filed Oct 29, 2018 20:41 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,485 | $0.00 Strike: $0.18 | $0.00 |
DisclosureSEC source: 0001209191-18-056421 · doc4.xml · derivative · entry 3 Ettenberg Seth · CIK 0001734419 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,085 Underlying: Common Stock · 11,485 shares Expires 2025-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares vests on September 3, 2015, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer. Read SEC document |
| October 25, 2018 Filed Oct 29, 2018 20:41 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | SaleCommon Stock | 11,485 | $8.46 | $97,201.00 |
DisclosureSEC source: 0001209191-18-056421 · doc4.xml · nonDerivative · entry 2 Ettenberg Seth · CIK 0001734419 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.06 to $8.67, inclusive. The reporting person undertakes to provide to Unum Therapeutics Inc., any security holder of Unum Therapeutics Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 25, 2018 Filed Oct 29, 2018 20:41 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | Exercise / conversionCommon Stock | 11,485 | $0.18 | $2,067.30 |
DisclosureSEC source: 0001209191-18-056421 · doc4.xml · nonDerivative · entry 1 Ettenberg Seth · CIK 0001734419 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,485 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 25, 2018 Filed Sep 26, 2018 22:41 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | SaleCommon Stock | 11,485 | $12.47 | $143,181.20 |
DisclosureSEC source: 0001209191-18-052358 · doc4.xml · nonDerivative · entry 2 Ettenberg Seth · CIK 0001734419 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.11 to $12.90, inclusive. The reporting person undertakes to provide to Unum Therapeutics Inc., any security holder of Unum Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 25, 2018 Filed Sep 26, 2018 22:41 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | Exercise / conversionCommon Stock | 11,485 | $0.18 | $2,067.30 |
DisclosureSEC source: 0001209191-18-052358 · doc4.xml · nonDerivative · entry 1 Ettenberg Seth · CIK 0001734419 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,485 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 24, 2018 Filed Sep 26, 2018 22:41 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,485 | $0.00 Strike: $0.18 | $0.00 |
DisclosureSEC source: 0001209191-18-052358 · doc4.xml · derivative · entry 3 Ettenberg Seth · CIK 0001734419 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 386,570 Underlying: Common Stock · 11,485 shares Expires 2025-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares vests on September 3, 2015, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.